Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01865812
NCT01865812CompletedPhase 2

A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis

Intercept Pharmaceuticals7 sites in 1 country27 target enrollmentStarted: December 3, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
27
Locations
7
Primary Endpoint
Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study was to determine if OCA had an effect on cholesterol levels in the blood in participants with primary biliary cirrhosis (PBC).

Detailed Description

This was a phase 2, open-label, multicenter study evaluating the effects of OCA on lipoprotein metabolism in participants with PBC; in particular, OCA's effects on high-density lipoprotein cholesterol. Nuclear magnetic resonance spectroscopy was utilized to quantify the changes in lipoprotein particle sizes and concentrations. Components of reverse cholesterol transport were also assessed.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Definite or probable PBC diagnosis as demonstrated by the presence of ≥ 2 of the following 3 diagnostic factors:
  • •History of elevated alkaline phosphatase levels for at least 6 months
  • •A positive anti-microbial antibody (AMA) titer or, if AMA negative or in low titer (<1:80), PBC-specific antibodies
  • •Liver biopsy consistent with PBC
  • •Taking UDCA for at least 12 months (stable dose for ≥ 3 months) prior to Day 0 or unable to tolerate UDCA (no UDCA for ≥ 3 months prior to Day 0).
  • •Contraception: Female participants must have been postmenopausal, surgically sterile, or if premenopausal, were prepared to use ≥ 1 effective (≤ 1% failure rate) method of contraception during the trial and until at least 30 days after the last dose of Investigational Product.
  • •Must have provided written informed consent and agreed to comply with the trial protocol.

Exclusion Criteria

  • •Participants with decompensated PBC (as determined by the Investigator).
  • •Severe pruritus or systemic treatment for pruritus (for example, treatment with bile acid sequestrants or rifampicin) within 2 months of Day
  • •History or presence of other significant liver diseases including:
  • •Active or chronic Hepatitis B or C virus infection
  • •Primary sclerosing cholangitis
  • •Alcoholic liver disease
  • •Definite autoimmune liver disease or overlap hepatitis
  • •Nonalcoholic steatohepatitis
  • •Note: Participants with Gilbert's disease or those with a history of hepatitis B who were currently antigen negative and seroconverted were not considered exclusionary.
  • •Uncontrolled diabetes or other uncontrolled or unstable medical condition that may have interfered with trial results.
  • •Administration of any of the following medications as specified below:
  • •Prohibited 28 days prior to Day 0: bile acid sequestrants including cholestyramine, colesevelam, colestipol or omega-3 fatty acid containing dietary supplements
  • •Prohibited 3 months prior to Day 0 and throughout trial participation: serum-lipid modifying agents including 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, fenofibrate or other fibrates, nicotinic acid and derivatives, ezetimibe, Vitamin E (other than as standard dietary supplement)
  • •Prohibited 6 months prior to Day 0 and throughout the trial participation: azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; budesonide and other systemic corticosteroids; potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)
  • •Prohibited 12 months prior to Day 0 and throughout the trial participation: antibodies or immunotherapy directed against interleukins or other cytokines or chemokines
  • •Planned change in diet or exercise habits during participation in the trial.
  • •Presence or history of clinically significant cardiac arrhythmias that may have prohibited the participant from participating in the trial.
  • •If female: known pregnancy, or had a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
  • •Recent (3 months prior to day 0) participation in another trial involving OCA or participation in another investigational trial (30 days prior to Day 0) and during the trial.

Arms & Interventions

OCA: 10 mg

Experimental

Obeticholic acid, oral administration, 10 milligrams (mg), 8 weeks

Intervention: Obeticholic Acid (Drug)

Outcomes

Primary Outcomes

Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration

Time Frame: Baseline, Week 8

Absolute Change From Baseline In HDL Particle Number

Time Frame: Baseline, Week 8

Absolute Change From Baseline In HDL Particle Size

Time Frame: Baseline, Week 8

Secondary Outcomes

  • Median Change From Week 8 In HDL Cholesterol Concentration At Week 12(Week 8, Week 12)
  • Median Change From Week 8 In HDL Particle Size At Week 12(Week 8, Week 12)
  • Median Change From Baseline In Albumin(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In HDL Cholesterol Concentration At Weeks 4, 8, and 12(Baseline, Week 4, Week 8, Week 12)
  • Absolute Change From Baseline In HDL Cholesterol Concentration(Baseline, Month 24/EOT)
  • Absolute Change From Baseline In HDL Particle Number(Baseline, Month 24/EOT)
  • Median Change From Baseline In Total LDL Particles(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In VLDL Particle Size(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In HDL Particle Number At Weeks 4, 8, and 12(Baseline, Week 4, Week 8, Week 12)
  • Median Change From Week 8 In HDL Particle Number At Week 12(Week 8, Week 12)
  • Maximum Plasma Concentration (Cmax) Of OCA And Conjugates(Week 8)
  • Median Change From Baseline In LDL Particle Size(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Time To Reach Cmax (Tmax) For OCA And Conjugates(Week 8)
  • Area Under The Concentration-time Curve From Hour 0 To Last Sampling Time (Hour 6) (AUC0-6) For OCA And Conjugates(Week 8)
  • Median Change From Baseline In Total Cholesterol(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In Low-density Lipoprotein (LDL) Cholesterol (Direct)(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In VLDL Particles(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In Lipoprotein-a(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In C-reactive Protein(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Glycoprotein A(Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In HDL Particle Size At Weeks 4, 8, and 12(Baseline, Week 4, Week 8, Week 12)
  • Median Change From Baseline In Very Low-density Lipoprotein (VLDL) Cholesterol(Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In Prebeta-1 HDL Concentration(Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Hyaluronic Acid(Baseline, Month 12, Month 24/EOT)
  • Median Change From Baseline In Total Deoxycholic Acid(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Total Triglycerides(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In Apolipoprotein B (ApoB)(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In Lecithin-cholesterol Acyltransferase Activity(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Fibroblast Growth Factor-19(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Alanine Aminotransferase(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Aspartate Aminotransferase(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Prothrombin Time(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Total Lithocholic Acid(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Hepatic Stiffness(Baseline, Month 12, Month 24/EOT)
  • Median Change From Baseline In Cholesteryl Ester Transfer Protein(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Macrophage Cholesterol Efflux(Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Alkaline Phosphatase(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Prothrombin International Normalized Ratio(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Amino-terminal Propeptide Of Type III Procollagen(Baseline, Month 12, Month 24/EOT)
  • Median Change From Baseline In Total Bile Acids(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Total Endogenous Bile Acid(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Total Cholic Acid(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Absolute Change From Baseline In HDL Particle Size(Baseline, Month 24/EOT)
  • Median Change From Baseline In Apolipoprotein A1 (ApoA1)(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In ApoA1/ApoB Ratio(Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Median Change From Baseline In Apolipoprotein E(Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose)
  • Participants With Lipoprotein X(Week 12 and Last Dose)
  • Median Change From Baseline In Gamma-glutamyl Transferase(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Total And Unconjugated (Direct) Bilirubin(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Total Chenodeoxycholic Acid(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)
  • Median Change From Baseline In Enhanced Liver Fibrosis (ELF) Score(Baseline, Month 12, Month 24/EOT)
  • Median Change From Baseline In Tissue Inhibitor Of Metalloproteinases 1(Baseline, Month 12, Month 24/EOT)
  • Median Change From Baseline In Total UDCA(Baseline, Month 6, Month 12, Month 18, Month 24/EOT)

Investigators

Sponsor
Intercept Pharmaceuticals
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (7)

Loading locations...

Similar Trials

Completed
Phase 3
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemia
NCT00092625Organon and Co442
Completed
Phase 3
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)Coronary DiseaseHypercholesterolemia
NCT00092612Organon and Co372
Completed
Phase 3
An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)Coronary DiseaseHypercholesterolemia
NCT00092638Organon and Co450
Completed
Phase 2
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?DiarrheaIrritable Bowel Syndrome
NCT00911612Mayo Clinic24
Completed
Phase 2
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol LevelsHyperlipidemias
NCT00813527Takeda213